ChromaDex Corporation provided earnings guidance for the year 2022. Looking forward, for the full year, the Company expects high single digit revenue growth, driven by its global e-commerce business and growth with partners.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.67 USD | +9.43% |
|
-2.91% | +86.71% |
Jun. 25 | ChromaDex Chief Financial Officer Brianna Gerber to Resign | MT |
Jun. 24 | ChromaDex Says Nicotinamide Riboside Shows 'Promising Effects' in Peripheral Artery Disease Trial | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+86.71% | 202M | |
+23.13% | 46.93B | |
+36.92% | 39.08B | |
-8.73% | 38.48B | |
+28.09% | 31.01B | |
-12.26% | 26.14B | |
+10.57% | 25.88B | |
+32.23% | 12.53B | |
-6.56% | 11.36B | |
-12.56% | 10.65B |
- Stock Market
- Equities
- CDXC Stock
- News ChromaDex Corporation
- ChromaDex Corporation Provides Earnings Guidance for the Year 2022